Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: Obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 368, Issue 1615, 2013, Pages

  Murphy, Dennis L ^a   Moya, Pablo R ^a   Fox, Meredith A ^a   Rubenstein, Liza M ^a   Wendland, Jens R ^a,c   Timpano, Kiara R ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b University of Miami   (United States)

^c PFIZER INC   (United States)

Author keywords

Clinical heterogeneity; Comorbidity; Genetic heterogeneity; Obsessive compulsive disorder; Serotonin

Indexed keywords

ABNORMALITY; BIOCHEMISTRY; BRAIN; GENE EXPRESSION; GENETIC STRUCTURE; GENOTYPE-ENVIRONMENT INTERACTION; HETEROGENEITY; HORMONE; MEDICINE; MENTAL HEALTH; MORBIDITY; NERVOUS SYSTEM DISORDER; NEUROLOGY; PHYSIOLOGY; SYMPTOM;

EXCITATORY AMINO ACID TRANSPORTER 3; SEROTONIN 1 RECEPTOR; SEROTONIN TRANSPORTER; SLC1A1 PROTEIN, HUMAN; SLC6A4 PROTEIN, HUMAN;

ANIMAL; CHROMOSOME 22; CHROMOSOME DELETION; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; GENETIC HETEROGENEITY; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; METABOLISM; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; PATHOLOGY; REVIEW; SYNAPTIC TRANSMISSION;

ANIMALS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EXCITATORY AMINO ACID TRANSPORTER 3; GENE-ENVIRONMENT INTERACTION; GENETIC HETEROGENEITY; HUMANS; MOOD DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPTIC TRANSMISSION;

EID: 84874542894     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2012.0435     Document Type: Review

References (251)

1. Angst J, Gamma A, Endrass J, Goodwin R, Ajdacic V, Eich D, Rössler W. 2004 Obsessive-compulsive severity spectrum in the community: prevalence, comorbidity, and course. Eur. Arch. Psychiat. Clin. Neurosci. 254, 156-164. (doi:10.1007/s00406-004-0459-4)
2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. 2005 Lifetime prevalence and age of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch. Gen. Psychiat. 62, 593-602. (doi:10.1001/archpsyc.62.6.593)
3. Saxena S, Rauch SL. 2000 Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiat. Clin. North Am. 23, 563-586. (doi:10.1016/S0193-953X(05)70181-7)
4. Mataix-Cols D, van den Heuvel OA. 2006 Common and distinct neural correlates of obsessive-compulsive and related disorders. Psychiat. Clin. North Am. 29, 391-410. (doi:10.1016/j.psc.2006.02.006)
5. LaSalle VH, Cromer KR, Nelson KN, Kazuba D, Justement L, Murphy DL. 2004 Diagnostic interview assessed neuropsychiatric disorder comorbidity in 334 individuals with obsessive-compulsive disorder. Depress. Anxiety 19, 163-173. (doi:10.1002/da.20009)
6. Murphy DL, Timpano KR, Wheaton MG, Greenberg BD, Miguel EC. 2010 Obsessive-compulsive disorder and its related disorders: a reappraisal of obsessive-compulsive spectrum concepts. Dialogues Clin. Neurosci. 12, 131-148.
7. Nestadt G et al. 2008 Obsessive-compulsive disorder: subclassification based on co-morbidity. Psychol. Med. 39, 1-11. (doi:10.1017/S0033291708004753)
8. Nestadt G, Samuels J, Riddle MA, Liang KY, Bienvenu OJ, Hoehn-Saric R, Grados M, Cullen B. 2001 The relationship between obsessive-compulsive disorder and anxiety and affective disorders: results from the Johns Hopkins OCD family study. Psychol. Med. 31, 481-487. (doi:10.1017/S0033291701003579)
9. Miguel EC et al. 2008 The Brazilian research consortium on obsessive-compulsive spectrum disorders: recruitment, assessment instruments, methods for the development of multicenter collaborative studies and preliminary results. Rev. Bras. Psiquiatr. 30, 185-196. (doi:10.1590/S1516-44462008000300003)
10. Hasler G et al. 2007 Familiality of factor analysis derived YBOCS dimensions in OCD-affected sibling pairs from the OCD collaborative genetics study. Biol. Psychiat. 61, 617-625. (doi:10.1016/j.biopsych.2006.05.040)
11. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. 2010 The epidemiology of obsessive-compulsive disorder in the national comorbidity survey replication. Mol. Psychiat. 15, 53-63. (doi:10.1038/mp.2008.94)
12. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS. 1994 Lifetime and 12-month prevalence of DSM-IIIR psychiatric disorders in the United States. Results from the national comorbidity survey. Arch. Gen. Psychiat. 51, 8-19. (doi:10.1001/archpsyc.1994.03950010008002)
13. Timpano KR, Rubenstein LM, Murphy DL. 2012 Phenomenological features and clinical impact of affective disorders in OCD: a focus on the bipolar disorder and OCD connection. Depress. Anxiety 29, 226-233. (doi:10.1002/da.20908)
14. Nestadt G, Bienvenu OJ, Cai G, Samuels J, Eaton WW. 1998 Incidence of obsessive-compulsive disorder in adults. J. Nerv. Ment. Dis. 186, 401-406. (doi:10.1097/00005053-199807000-00003)
15. Nestadt G, Samuels JF, Romanoski AJ, Folstein MF, McHugh PR. 1994 Obsessions and compulsions in the community. Acta Psychiat. Scand. 89, 219-224. (doi:10.1111/j.1600-0447.1994.tb01504.x)
16. De Luca V, Gershenzon V, Burroughs E, Javaid N, Richter MA. 2011 Age at onset in Canadian OCD patients: mixture analysis and systematic comparison with other studies. J. Affect. Disord. 133, 300-304. (doi:10.1016/j.jad.2011.03.041)
17. Delorme R, Golmard JL, Chabane N, Millet B, Krebs MO, Mouren-Simeoni MC, Leboyer M. 2005 Admixture analysis of age at onset in obsessive-compulsive disorder. Psychol. Med. 35, 237-243. (doi:10.1017/S0033291704003253)
18. Hantouche EG, Demonfaucon C. 2008 Resistant obsessive-compulsive disorder (ROC): clinical picture, predictive factors and influence of affective temperaments. Encephale 34, 611-617. (doi:10.1016/j.encep.2007.12.008)
19. Hanna GL, Veenstra-VanderWeele J, Cox NJ, Boehnke M, Himle JA, Curtis GC, Leventhal BL, Cook EH. 2002 Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. Am. J. Med. Genet. 114, 541-552. (doi:10.1002/ajmg.10519)
20. Willour VL et al. 2004 Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. Am. J. Hum. Genet. 75, 508-513. (doi:10.1086/423899)
21. Hanna GL et al. 2007 Evidence for a susceptibility locus on chromosome 10p15 in early-onset obsessive-compulsive disorder. Biol. Psychiat. 62, 856-862. (doi:10.1016/j.biopsych.2007.01.008)
22. Shugart YY et al. 2006 Genomewide linkage scan for obsessive-compulsive disorder: evidence for susceptibility loci on chromosomes 3q, 7p, 1q, 15q, and 6q. Mol. Psychiat. 11, 763-770. (doi:10.1038/ sj.mp.4001847)
23. Samuels JF et al. 2006 The OCD collaborative genetics study: methods and sample description. Am. J. Med. Genet. B Neuropsychiat. Genet. 141B, 201-207. (doi:10.1002/ajmg.b.30224)
24. Wang Y et al. 2009 Gender differences in genetic linkage and association on 11p15 in obsessive-compulsive disorder families. Am. J. Med. Genet. B Neuropsychiat. Genet. 150B, 33-40. (doi:10.1002/ajmg.b.30760)
25. Samuels J et al. 2007 Significant linkage to compulsive hoarding on chromosome 14 in families with obsessive-compulsive disorder: results from the OCD collaborative genetics study. Am. J. Psychiat. 164, 493-499. (doi:10.1176/appi.ajp.164.3.493)
26. Psychiatric GWAS Consortium Steering Committee. 2009 A framework for interpreting genome-wide association studies of psychiatric disorders. Mol. Psychiat. 14, 10-17. (doi:10.1038/mp.2008.126)
27. Sklar P et al. 2008 Whole-genome association study of bipolar disorder. Mol. Psychiat. 13, 558-569. (doi:10.1038/sj.mp.4002151)
28. Stewart SE et al. In press. Genome-wide association study of obsessive-compulsive disorder. Mol. Psychiat. (doi:10.1038/mp.2012.85)
29. Welch JM et al. 2007 Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 448, 894-900. (doi:10.1038/nature06104)
30. Hettema JM, Neale MC, Kendler KS. 2001 A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am. J. Psychiat. 158, 1568-1578. (doi:10.1176/appi.ajp.158.10.1568)
31. Nestadt G, Samuels J, Riddle M, Bienvenu III OJ, Liang KY, LaBuda M, Walkup J, Grados M, Hoehn-Saric R. 2005 A family study of obsessive-compulsive disorder. Arch. Gen. Psychiat. 57, 358-363. (doi:10.1001/archpsyc.57.4.358)
32. Pauls DL, Alsobrook II JP, Goodman W, Rasmussen S, Leckman JF. 1995 A family study of obsessive-compulsive disorder. Am. J. Psychiat. 152, 76-84.
33. Nestadt G et al. 2000 Complex segregation analysis provides compelling evidence for a major gene underlying obsessive-compulsive disorder and for heterogeneity by sex. Am. J. Hum. Genet. 67, 1611-1616. (doi:10.1086/316898)
34. Hanna GL, Himle JA, Curtis GC, Gillespie BW. 2005 A family study of obsessive-compulsive disorder with pediatric probands. Am. J. Med. Genet. B Neuropsychiat. Genet. 134, 13-19. (doi:10.1002/ajmg.b.30138)
35. Cavallini MC, Pasquale L, Bellodi L, Smeraldi E. 1999 Complex segregation analysis for obsessive compulsive disorder and related disorders. Am. J. Med. Genet. 88, 38-43. (doi:10.1002/(SICI)1096-8628(19990205)88:1,38::AIDAJMG7.3.0.CO;2-#)
36. Alsobrook JP, Leckman JF, Goodman WK, Rasmussen SA, Pauls DL. 1999 Segregation analysis of obsessive-compulsive disorder using symptom based factor scores. Am. J. Med. Genet. 88, 669-675. (doi:10.1002/(SICI)1096-8628(1999 1215)88:6,669::AID-AJMG17.3.0.CO;2-N)
37. Eapen V, Pauls DL, Robertson MM. 2006 The role of clinical phenotypes in understanding the genetics of obsessive-compulsive disorder. J. Psychosom. Res. 61, 359-364. (doi:10.1016/j.jpsychores.2006.07.021)
38. Cryan EM, Butcher GJ, Webb MG. 1992 Obsessive- compulsive disorder and paraphilia in a monozygotic twin pair. Br. J. Psychiat. 161, 694-698. (doi:10.1192/bjp.161.5.694)
39. Marks IM, Crowe M, Drewe E, Young J, Dewhurst WG. 1969 Obsessive compulsive neurosis in identical twins. Br. J. Psychiat. 115, 991-998. (doi:10.1192/bjp.115.526.991)
40. McGuffin P, Mawson D. 1980 Obsessive-compulsive neurosis: two identical twin pairs. Br. J. Psychiat. 137, 285-287. (doi:10.1192/bjp.137.3.285)
41. Woodruff R, Pitts Jr FN, 1964 Monozygotic twins with obsessional illness. Am. J. Psychiat. 120, 1075-1080.
42. Carey G, Gottesman II. 1981 Twin and family studies of anxiety, phobic, and obsessive disorders. In Anxiety: new research and changing concepts (eds DF Klein, JG Rabkin), pp. 117-136. New York, NY: Raven Press.
43. Inouye E. 1965 Similar and dissimilar manifestations of obsessive-compulsive neuroses in monozygotic twins. Am. J. Psychiat. 121, 1171-1175.
44. Jonnal AH, Gardner CO, Prescott CA, Kendler KS. 2000 Obsessive and compulsive symptoms in a general population sample of female twins. Am. J. Med. Genet. 96, 791-796. (doi:10.1002/1096-8628(20001204)96:6,791::AID-AJMG19.3.0.CO;2-C)
45. van Grootheest DS, Cath DC, Beekman AT, Boomsma DI. 2005 Twin studies on obsessive-compulsive disorder: a review. Twin Res. Hum. Genet. 8, 450-458.
46. Hemmings SM, Stein DJ. 2006 The current status of association studies in obsessive-compulsive disorder. Psychiat. Clin. North Am. 29, 411-444. (doi:10.1016/j.psc.2006.02.011)
47. Torres GE, Caron MG. 2003 Center stage for the serotonin transporter: a gain-of-function polymorphism in persons with obsessive-compulsive disorder. Mol. Pharmacol. 64, 196-198. (doi:10.1124/mol.64.2.196)
48. Murphy DL, Lerner A, Rudnick G, Lesch KP. 2004 Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol. Interv. 4, 109-123. (doi:10.1124/mi.4.2.8)
49. Altemus M, Murphy DL, Greenberg B, Lesch KP. 1996 Intact coding region of the serotonin transporter gene in obsessive-compulsive disorder. Am. J. Med. Genet. 67, 409-411. (doi:10.1002/(SICI)1096-8628(19960726)67:4,409::AID-AJMG 16.3.0.CO;2-N)
50. Bengel D, Greenberg BD, Cora-Locatelli G, Altemus M, Heils A, Li Q, Murphy DL. 1994 Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder. Mol. Psychiat. 4, 463-466. (doi:10.1038/sj.mp.4000550)
51. McDougle CJ, Epperson CN, Price LH, Gelernter J. 1998 Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive-compulsive disorder. Mol. Psychiat. 3, 270-273. (doi:10.1038/sj.mp.4000391)
52. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. 1994 Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch. Gen. Psychiat. 51, 302-308. (doi:10.1001/archpsyc.1994.03950040046006)
53. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. 1985 Obsessive-compulsive disorder and serotonin: is there a connection? Biol. Psychiat. 20, 1174-1188. (doi:10.1016/0006- 3223(85)90176-3)
54. Hollander E, DeCaria C, Gully R, Nitescu A, Suckow RF, Gorman JM, Klein DF, Liebowitz MR. 1991 Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to metachlorophenylpiperazine in obsessive-compulsive disorder. Psychiat. Res. 36, 1-17. (doi:10.1016/0165-1781(91)90113-4)
55. Zohar J, Insel TR. 1987 Drug treatment of obsessive-compulsive disorder. J. Affect. Disord. 13, 193-202. (doi:10.1016/0165-0327 (87)90023-1)
56. Pigott TA, Hill JL, Grady TA, L'Heureux F, Bernstein S, Rubenstein CS, Murphy DL. 1993 A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol. Psychiat. 33, 3-14. (doi:10.1016/0006-3223(93)90272-F)
57. Lesch K-P et al. 1996 Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527-1531. (doi:10.1126/science.274.5292.1527)
58. Bloch MH, Landeros-Weisenberger A, Sen S, Dombrowski P, Kelmendi B, Coric V, Pittenger C, Leckman JF. 2008 Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. Am. J. Med. Genet. B Neuropsychiat. Genet. 147, 850-858. (doi:10.1002/ajmg.b.30699)
59. Dickel DE et al. 2007 Association studies of serotonin system candidate genes in early-onset obsessive-compulsive disorder. Biol. Psychiat. 61, 322-329. (doi:10.1016/j.biopsych.2006.09.030)
60. Hu XZ et al. 2006 Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 78, 815-826. (doi:10.1086/503850)
61. Wendland JR, DeGuzman TB, McMahon F, Rudnick G, Detera-Wadleigh SD, Murphy DL. 2008 SERT Ileu425Val in autism, Asperger syndrome and obsessive-compulsive disorder. Psychiat. Genet. 18, 31-39. (doi:10.1097/YPG.0b013e3282f08a06)
62. Wendland JR, Kruse MR, Cromer KC, Murphy DL. 2007 A large case-control study of common functional SLC6A4 and BDNF variants in obsessive-compulsive disorder. Neuropsychopharmacology 33, 1476. (doi:10.1038/sj.npp.1301515)
63. Wendland JR, Moya PR, Kruse MR, Ren-Patterson RF, Jensen CL, Timpano KR, Murphy DL. 2008 A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. Hum. Mol. Genet. 17, 717-723. (doi:10. 1093/hmg/ddm343)
64. Murphy DL, Moya PR. 2011 Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G × G and G × E differences in health and disease. Curr. Opin. Pharmacol. 11, 3-10. (doi:10.1016/j.coph.2011.02.008)
65. Pezawas L et al. 2008 Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol. Psychiat. 13, 709-716. (doi:10.1038/mp.2008.32)
66. Uher R, McGuffin P. 2009 The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression. Mol. Psychiat. 15, 18-22. (doi:10.1038/mp.2009.123)
67. Caspi A et al. 2003 Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386-389. (doi:10.1126/science.1083968)
68. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. 2010 Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am. J. Psychiat. 167, 509-527. (doi:10.1176/appi.ajp.2010.09101452)
69. Ozaki N, Goldman D, Kaye WH, Plotnicov K, Greenberg BD, Lappalainen J, Rudnick G, Murphy DL. 2003 Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol. Psychiat. 8, 933-936. (doi:10.1038/sj.mp.4001365)
70. Delorme R et al. 2005 Support for the association between the rare functional variant I425V of the serotonin transporter gene and susceptibility to obsessive compulsive disorder. Mol. Psychiat. 10, 1059-1061. (doi:10.1038/sj.mp.4001728)
71. Kilic F, Murphy DL, Rudnick G. 2003 A human serotonin transporter mutation causes constitutive activation of transport activity. Mol. Pharmacol. 64, 440-446. (doi:10.1124/mol.64.2.440)
72. Holmes A. 2008 Genetic variation in corticoamygdala serotonin function and risk for stress-related disease. Neurosci. Biobehav. Rev. 32, 1293-1314. (doi:10.1016/j.neubiorev.2008.03.006)
73. Greenberg BD, Tolliver TJ, Huang SJ, Li Q, Bengel D, Murphy DL. 1999 Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am. J. Med. Genet. 88, 83-87. (doi:10.1002/(SICI)1096-8628(19990205)88: 1,83::AID-AJMG15.3.0.CO;2-0)
74. Lothe A, Boni C, Costes N, Gorwood P, Bouvard S, Le Bars D, Lavenne F, Ryvlin P. 2009 Association between triallelic polymorphism of the serotonin transporter and [18F]MPPF binding potential at 5-HT1A receptors in healthy subjects. NeuroImage 47, 482-492. (doi:10.1016/j.neuroimage.2009.04.067)
75. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, Weinberger D. 2005 A susceptibility gene for affective disorders and the response of the human amygdala. Arch. Gen. Psychiat. 62, 146-152. (doi:10.1001/archpsyc.62.2.146)
76. Murphy DL, Uhl GR, Holmes A, Ren-Patterson R, Hall FS, Sora I, Detera-Wadleigh S, Lesch K-P. 2003 Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. Genes Brain Behav. 2, 350-364. (doi:10.1046/j.1601-1848.2003.00049.x)
77. Murphy DL, Lesch KP. 2008 Targeting the murine serotonin transporter: insights into human neurobiology. Nat. Rev. Neurosci. 9, 85-96. (doi:10.1038/nrn2284)
78. Fox MA, Jensen CL, French HT, Stein AR, Huang SJ, Tolliver TJ, Murphy DL. 2008 Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice. Psychopharmacology 201, 203-218. (doi:10.1007/s00213-008-1268-7)
79. Jennings KA et al. 2006 Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission. J. Neurosci. 26, 8955-8964. (doi:10.1523/JNEUROSCI.5356-05.2006)
80. Murphy DL, Fox MA, Timpano KR, Moya PR, Ren-Patterson R, Andrews AM, Holmes A, Lesch K-P, Wendland JR. 2008 How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology 55, 932-960. (doi:10.1016/j.neuropharm.2008.08.034)
81. Homberg JR et al. 2007 Characterization of the serotonin transporter knockout rat: a selective change in the functioning of the serotonergic system. Neuroscience 146, 1662-1676. (doi:10.1016/j.neuroscience.2007.03.030)
82. Homberg JR, van den Bos R, den Heijer E, Suer R, Cuppen E. 2008 Serotonin transporter dosage modulates long-term decision-making in rat and human. Neuropharmacology 55, 80-84. (doi:10.1016/j.neuropharm.2008.04.016)
83. Homberg JR, Contet C. 2009 Deciphering the interaction of the corticotropin-releasing factor and serotonin brain systems in anxiety-related disorders. J. Neurosci. 29, 13743-13745. (doi:10.1523/JNEUROSCI.4362-09.2009)
84. Shugart YY et al. 2009 A family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder in 378 families. Am. J. Med. Genet. B Neuropsychiat. Genet. 150B, 886-892. (doi:10.1002/ajmg.b.30914)
85. Dickel DE et al. 2006 Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch. Gen. Psychiat. 63, 778-785. (doi:10.1001/archpsyc.63.7.778)
86. Wang Y et al. 2010 A screen of SLC1A1 for OCD related alleles. Am. J. Med. Genet. B Neuropsychiat. Genet. 153, 675-679.
87. Stewart SE et al. 2007 Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am. J. Med. Genet. B Neuropsychiat. Genet. 144B, 1027-1033. (doi:10.1002/ajmg.b.30533)
88. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. 2006 Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch. Gen. Psychiat. 63, 769-776. (doi:10.1001/archpsyc.63.7.769)
89. Wendland JR, Moya PR, Timpano KR, Anavitarte AP, Kruse MR, Wheaton MG, Ren-Patterson RF, Murphy DL. 2009 A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Arch. Gen. Psychiat. 66, 408-416. (doi:10.1001/archgenpsychiatry.2009.6)
90. Veenstra-Vanderweele J et al. 2012 Functional studies and rare variant screening of SLC1A1/EAAC1 in males with obsessive-compulsive disorder. Psychiat. Genet. 22, 256-260. (doi:10.1097/YPG. 0b013e328353fb63)
91. Arnold PD et al. 2009 Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulated glutamatergic concentration in pediatric obsessive-compulsive disorder. Psychiat. Res. 172, 136-139. (doi:10.1016/j.pscychresns.2009.02.005)
92. Rosenberg DR, Hanna GL. 2000 Genetic and imaging strategies in obsessive-compulsive disorder: potential implications for treatment development. Biol. Psychiat. 48, 1210-1222. (doi:10.1016/S0006-3223(00)01073-8)
93. Moore GJ, MacMaster FP, Stewart C, Rosenberg DR. 1998 Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiat. 37, 663-667. (doi:10.1097/00004583-199806000-00017)
94. Wu K, Hanna GL, Rosenberg DR, Arnold PD. 2012 The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol. Biochem. Behav. 100, 726-735. (doi:10.1016/j.pbb.2011.10.007)
95. Coric V et al. 2005 Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol. Psychiat. 58, 424-428. (doi:10.1016/j.biopsych.2005.04.043)
96. Grant P, Lougee L, Hirschtritt M, Swedo SE. 2007 An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 17, 761-767. (doi:10.1089/cap.2007.0021)
97. Schwenkreis P, Liepert J, Witscher K, Fischer W, Weiller C, Malin JP, Tegenthoff M. 2000 Riluzole suppresses motor cortex facilitation in correlation to its plasma level. A study using transcranial magnetic stimulation. Exp. Brain Res. 135, 293-299. (doi:10.1007/s002210000532)
98. Hezel DM, Beattie K, Stewart SE. 2009 Memantine as an augmenting agent for severe pediatric OCD. Am. J. Psychiat. 166, 237. (doi:10.1176/appi.ajp. 2008.08091427)
99. Poyurovsky M, Weizman R, Weizman A, Koran L. 2005 Memantine for treatment-resistant OCD. Am. J. Psychiat. 162, 2191-2192. (doi:10.1176/appi.ajp.162.11.2191-a)
100. Pasquini M, Biondi M. 2006 Memantine augmentation for refractory obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiat. 30, 1173-1175. (doi:10.1016/j.pnpbp. 2006.04.013)
101. Feusner JD, Kerwin L, Saxena S, Bystritsky A. 2009 Differential efficacy of memantine for obsessive- compulsive disorder versus generalized anxiety disorder: an open-label trial. Psychopharmacol. Bull. 42, 81-93.
102. Aboujaoude E, Barry JJ, Gamel N. 2009 Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J. Clin. Psychopharmacol. 29, 51-55. (doi:10.1097/JCP.0b013e318192e9a4)
103. Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, Jenike MA. 2010 A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J. Clin. Psychopharmacol. 30, 34-39. (doi:10.1097/JCP. 0b013e3181c856de)
104. Machado-Vieira R, Salvadore G, Ibrahim LA, Diaz-Granados N, Zarate Jr CA. 2009 Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr. Pharm. Des. 15, 1595-1611. (doi:10.2174/138161209788168010)
105. Rodriguez CI, Kegeles LS, Flood P, Simpson HB. 2011 Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatmentresistant obsessive-compulsive disorder. J. Clin. Psychiat. 72, 567-569. (doi:10.4088/JCP.10l06653)
106. Bloch MH et al. 2012 Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol. Psychiat. 72, 964-970. (doi:10.1016/j.biopsych.2012.05.028)
107. Alonso P et al. 2012 Association between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorder. J. Psychiat. Neurosci. 37, 273-281. (doi:10.1503/jpn.110109)
108. Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA. 2004 Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology 174, 530-538. (doi:10.1007/s00213-004-1847-1)
109. Hall D, Dhilla A, Charalambous A, Gogos JA, Karayiorgou M. 2003 Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am. J. Hum. Genet. 73, 370-376. (doi:10.1086/377003)
110. Timpano KR, Schmidt NB, Wheaton MG, Wendland JR, Murphy DL. 2011 Consideration of the BDNF gene in relation to two phenotypes: hoarding and obesity. J. Abnorm. Psychol. 120, 700-707. (doi:10.1037/a0024159)
111. Ren-Patterson RF, Cochran LW, Holmes A, Sherrill S, Huang SJ, Tolliver T, Lesch K-P, Lu B, Murphy DL. 2005 Loss of brain-derived neurotrophic factor gene allele exacerbates brain monoamine deficiencies and increases stress abnormalities of serotonin transporter knockout mice. J. Neurosci. Res. 79, 756-771. (doi:10.1002/jnr.20410)
112. Nicolini H et al. 1996 DRD2, DRD3 and 5HT2A receptor genes polymorphisms in obsessive- compulsive disorder. Mol. Psychiat. 1, 461-465.
113. Hemmings SM, Kinnear CJ, Niehaus DJ, Moolman-Smook JC, Lochner C, Knowles JA, Corfield VA, Stein DJ. 2003 Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 13, 93-98. (doi:10.1016/S0924-977X(02)00129-3)
114. Cruz C, Camarena B, King N, Paez F, Sidenberg D, de la Fuente JR, Nicolini H. 1997 Increased prevalence of the seven-repeat variant of the dopamine D4 receptor gene in patients with obsessive-compulsive disorder with tics. Neurosci. Lett. 231, 1-4. (doi:10.1016/S0304-3940(97)00523-5)
115. Millet B et al. 2003 Association between the dopamine receptor D4 (DRD4) gene and obsessive-compulsive disorder. Am. J. Med. Genet. B Neuropsychiat. Genet. 116, 55-59. (doi:10.1002/ ajmg.b.10034)
116. Billett EA et al. 1998 Investigation of dopamine system genes in obsessive-compulsive disorder. Psychiat. Genet. 8, 163-169. (doi:10.1097/00041444-199800830-00005)
117. Catalano M, Sciuto G, Di Bella D, Novelli E, Nobile M, Bellodi L. 1994 Lack of association between obsessive-compulsive disorder and the dopamine D3 receptor gene: some preliminary considerations. Am. J. Med. Genet. 54, 253-255. (doi:10.1002/ajmg.1320540312)
118. Walitza S et al. 2008 Transmission disequilibrium studies in early onset of obsessive-compulsive disorder for polymorphisms in genes of the dopaminergic system. J. Neural. Transm. 115, 1071-1078. (doi:10.1007/s00702-008-0051-6)
119. Karayiorgou M, Sobin C, Blundell ML, Galke BL, Malinova L, Goldberg P, Ott J, Gogos JA. 1999 Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biol. Psychiat. 45, 1178-1189. (doi:10.1016/S0006-3223(98)00319-9)
120. Camarena B, Rinetti G, Cruz C, Gomez A, de la Fuente JR, Nicolini H. 2001 Additional evidence that genetic variation of MAO-A gene supports a gender subtype in obsessive-compulsive disorder. Am. J. Med. Genet. 105, 279-282. (doi:10.1002/ajmg.1323)
121. Pulver AE et al. 1994 Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J. Nerv. Ment. Dis. 182, 476-478. (doi:10.1097/00005053-199408000-00010)
122. Bienvenu OJ et al. 2008 Sapap3 and pathological grooming in humans: results from the OCD collaborative genetics study. Am. J. Med. Genet. B Neuropsychiat. Genet. 150, 710-720. (doi:10.1002/ajmg.b.30897)
123. Gothelf D et al. 2004 Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. Am. J. Med. Genet. B Neuropsychiat. Genet. 126, 99-105. (doi:10.1002/ajmg.b.20124)
124. Feinstein C, Eliez S, Blasey C, Reiss AL. 2002 Psychiatric disorders and behavioral problems in children with velocardiofacial syndrome: usefulness as phenotypic indicators of schizophrenia risk. Biol. Psychiat. 51, 312-318. (doi:10.1016/S0006-3223(01)01231-8)
125. Papolos DF, Faedda GL, Veit S, Goldberg R, Morrow B, Kucherlapati R, Shprintzen RJ. 1996 Bipolar spectrum disorders in patients diagnosed with velocardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder? Am. J. Psychiat. 153, 1541-1547.
126. Saunders-Pullman R et al. 2002 Myoclonus dystonia: possible association with obsessive-compulsive disorder and alcohol dependence. Neurology 58, 242-245. (doi:10.1212/WNL.58.2.242)
127. Doheny D et al. 2002 Clinical findings of a myoclonus-dystonia family with two distinct mutations. Neurology 59, 1244-1246. (doi:10.1212/WNL.59.8.1244)
128. Marechal L et al. 2003 Severe myoclonus-dystonia syndrome associated with a novel epsilonsarcoglycan gene truncating mutation. Am. J. Med. Genet. B Neuropsychiat. Genet. 119, 114-117. (doi:10.1002/ajmg.b.10062)
129. Zimprich A et al. 2001 Mutations in the gene encoding epsilon-sarcoglycan cause myoclonusdystonia syndrome. Nat. Genet. 29, 66-69. (doi:10.1038/ng709)
130. Verkerk AJ, Mathews CA, Joosse M, Eussen BH, Heutink P, Oostra BA. 2003 CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. Genomics 82, 1-9. (doi:10.1016/S0888-7543(03)00097-1)
131. Boghosian-Sell L, Comings DE, Overhauser J. 1996 Tourette syndrome in a pedigree with a 7;18 translocation: identification of a YAC spanning the translocation breakpoint at 18q22.3. Am. J. Hum. Genet. 59, 999-1005.
132. Petek E, Windpassinger C, Vincent JB, Cheung J, Boright AP, Scherer SW, Kroisel PM, Wagner K. 2001 Disruption of a novel gene (IMMP2L) by a breakpoint in 7q31 associated with Tourette syndrome. Am. J. Hum. Genet. 68, 848-858. (doi:10.1086/319523)
133. Diaz-Anzaldua A, Joober R, Riviere JB, Dion Y, Lesperance P, Chouinard S, Richer F, Rouleau GA, 2004 Association between 7q31 markers and Tourette syndrome. Am. J. Med. Genet. A 127, 17-20. (doi:10.1002/ajmg.a.20631)
134. Grimes DA, Han F, Lang AE, St George-Hyssop P, Racacho L, Bulman DE. 2002 A novel locus for inherited myoclonus-dystonia on 18p11. Neurology 59, 1183-1186. (doi:10.1212/WNL.59.8.1183)
135. de Carvalho Aguiar P, Fazzari M, Jankovic J, Ozelius LJ. 2004 Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder. Mov. Disord. 19, 1237-1238. (doi:10.1002/mds.20156)
136. Heiman G, Ottman R, Saunders-Pullman R, Ozelius L, Risch N, Bressman S. 2006 Obsessive-compulsive disorder is not a clinical manifestation of the DYT1 dystonia gene. Am. J. Med. Genet. B Neuropsychiat. Genet. 144, 361-364. (doi:10.1002/ajmg.b.30431)
137. Bihari K, Hill JL, Murphy DL. 1992 Obsessive-compulsive characteristics in patients with idiopathic spasmodic torticollis. Psychiat. Res. 42, 267-272. (doi:10.1016/0165-1781(92)90118-M)
138. Bihari K, Pigott TA, Hill JL, Murphy DL. 1992 Blepharospasm and obsessive-compulsive disorder. J. Nerv. Ment. Dis. 180, 130-132. (doi:10.1097/00005053-199202000-00011)
139. Voon V, Butler T, Ekanayake V, Gallea C, Ameli R, Hallet M. 2010 Psychiatric symptoms associated with focal hand dystonia. Mov. Disord. 25, 2249-2252. (doi:10.1002/mds.23250)
140. Cavallaro R, Galardi G, Cavallini MC, Henin M, Amodio S, Bellodi L, Comi G. 2002 Obsessive compulsive disorder among idiopathic focal dystonia patients: an epidemiological and family study. Biol. Psychiat. 52, 356-361. (doi:10.1016/S0006-3223(02)01332-X)
141. Chan P, Gonzalez-Maeso J, Ruf F, Bishop DF, Hof PR, Sealfon SC. 2005 Epsilon-sarcoglycan immunoreactivity and mRNA expression in mouse brain. J. Comp. Neurol. 482, 50-73. (doi:10.1002/cne.20377)
142. Rauch SL, Whalen PJ, Curran T, Shin LM, Coffey BJ, Savage CR, Mclnerney SC, Baer L, Jenike MA. 2001 Probing striato-thalamic function in obsessive- compulsive disorder and Tourette syndrome using neuroimaging methods. Adv. Neurol. 85, 207-224.
143. Lerner A et al. 2009 Involvement of insula and cingulate cortices in control and suppression of natural urges. Cereb. Cortex 19, 218-223. (doi:10.1093/cercor/bhn074)
144. McLean-Tooke A, Spickett GP, Gennery AR. 2007 Immunodeficiency and autoimmunity in 22q11.2 deletion syndrome. Scand. J. Immunol. 66, 1-7. (doi:10.1111/j.1365-3083.2007.01949.x)
145. Antshel KM, Kates WR, Roizen N, Fremont W, Shprintzen RJ. 2005 22q11.2 deletion syndrome: genetics, neuroanatomy and cognitive/behavioral features keywords. Neuropsychol. Dev. Cogn. C Child Neuropsychol. 11, 5-19. (doi:10.1080/09297040590911185)
146. Eichstedt JA, Arnold SL. 2001 Childhood-onset obsessive-compulsive disorder: a tic-related subtype of OCD? Clin. Psychol. Rev. 21, 137-157. (doi:10.1016/S0272-7358(99)00044-6)
147. Fisher SE et al. 2002 A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. Am. J. Hum. Genet. 70, 1183-1196. (doi:10.1086/340112)
148. Azzam A, Mathews CA. 2003 Meta-analysis of the association between the catecholamine-O-methyltransferase gene and obsessive-compulsive disorder. Am. J. Med. Genet. B Neuropsychiat. Genet. 123, 64-69. (doi:10.1002/ajmg.b.20013)
149. Michaelovsky E et al. 2008 Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS. Int. J. Neuropsychopharmacol. 11, 351-363. (doi:10.1017/S1461145707008085)
150. Pooley EC, Fineberg N, Harrison PJ. 2007 The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and metaanalysis. Mol. Psychiat. 12, 556-561. (doi:10.1038/sj.mp.4001951)
151. Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A, Nussbaum R, Weinberger DR, Berman KF. 2005 Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat. Neurosci. 8, 594-596. (doi:10.1038/nn1438)
152. Cryan JF, Slattery DA. 2007 Animal models of mood disorders: recent developments. Curr. Opin. Psychiat. 20, 1-7. (doi:10.1097/YCO.0b013e328 0117733)
153. Cryan JF, Holmes A. 2005 The ascent of mouse: advances in modelling human depression and anxiety. Nat. Rev. Drug Discov. 4, 775-790. (doi:10.1038/nrd1825)
154. Post AM, Weyers P, Holzer P, Painsipp E, Pauli P, Wultsch T, Reif A, Lesch K-P. 2011 Geneenvironment interaction influences anxiety-like behavior in ethologically based mouse models. Behav. Brain Res. 218, 99-105. (doi:10.1016/j.bbr.2010.11.031)
155. Savignac HM, Hyland NP, Dinan TG, Cryan JF. 2011 The effects of repeated social interaction stress on behavioural and physiological parameters in a stress-sensitive mouse strain. Behav. Brain Res. 216, 576-584. (doi:10.1016/j.bbr.2010.08.049)
156. Muller JM, Morelli E, Ansorge M, Gingrich JA. 2011 Serotonin transporter deficient mice are vulnerable to escape deficits following inescapable shocks. Genes Brain Behav. 10, 166-175. (doi:10.1111/j. 1601-183X.2010.00652.x)
157. Neumann ID, Wegener G, Homberg JR, Cohen H, Slattery DA, Zohar J, Olivier JDA, Mathé AA. 2010 Animal models of depression and anxiety: What do they tell us about human condition? Prog. Neuropsychopharmacol. Biol. Psychiat. 35, 1357-1375. (doi:10.1016/j.pnpbp.2010.11.028)
158. Cryan JF et al. 2004 Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc. Natl Acad. Sci. USA 101, 8186-8191. (doi:10.1073/pnas.0401080101)
159. Lesch KP. 2011 When the serotonin transporter gene meets adversity: the contribution of animal models to understanding epigenetic mechanisms in affective disorders and resilience. Curr. Top. Behav. Neurosci. 7, 251-280. (doi:10.1007/7854_2010_109)
160. Hoyle D et al. 2011 Shared changes in gene expression in frontal cortex of four genetically modified mouse models of depression. Eur. Neuropsychopharmacol. 21, 3-10. (doi:10.1016/j.euroneuro.2010.09.011)
161. Ting JT, Feng G. 2011 Neurobiology of obsessive- compulsive disorder: insights into neural circuitry dysfunction through mouse genetics. Curr. Opin. Neurobiol. 21, 842-848. (doi:10.1016/j.conb.2011. 04.010)
162. Tordera RM, Garcia-Garcia AL, Elizalde N, Segura V, Aso E, Venzala E, Ramãrez MJ, Del Rio J. 2011 Chronic stress and impaired glutamate function elicit a depressive-like phenotype and common changes in gene expression in the mouse frontal cortex. Eur. Neuropsychopharmacol. 21, 23-32. (doi:10.1016/j.euroneuro.2010.06.016)
163. Joel D, Zohar O, Afek M, Hermesh H, Lerner L, Kuperman R, Grossisseroff R, Weizman A, Inzelberg R. 2005 Impaired procedural learning in obsessive-compulsive disorder and Parkinson's disease, but not in major depressive disorder. Behav. Brain Res. 157, 253-263. (doi:10.1016/j.bbr.2004.07.006)
164. Dodman NH, Karlsson EK, Moon-Fanelli A, Galdzicka M, Perloski M, Shuster L, Lindblad-Toh K, Ginns EI. 2009 A canine chromosome 7 locus confers compulsive disorder susceptibility. Mol. Psychiat. 15, 8-10. (doi:10.1038/mp.2009.111)
165. Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, Paylor R. 2009 Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology 204, 361-373. (doi:10.1007/s00213-009-1466-y)
166. Albelda N, Joel D. 2011 Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates. Neurosci. Biobehav. Rev. 36, 47-63. (doi:10.1016/j.neubiorev.2011.04.006)
167. Wang L, Simpson HB, Dulawa SC. 2009 Assessing the validity of current mouse genetic models of obsessive-compulsive disorder. Behav. Pharmacol. 20, 119-133. (doi:10.1097/FBP.0b013e32832a80ad)
168. Joel D. 2006 Current animal models of obsessive compulsive disorder: a critical review. Prog. Neuropsychopharmacol. Biol. Psychiat. 30, 374-388. (doi:10.1016/j.pnpbp.2005.11.006)
169. Korff S, Harvey BH. 2006 Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiat. Clin. North Am. 29, 371-390. (doi:10.1016/j.psc.2006.02.007)
170. Holden C, Travis J. 2010 Profile: Nicholas Dodman. Can dogs behaving badly suggest a new way to treat OCD? Science 329, 386-387. (doi:10.1126/science.329.5990.386)
171. Shmelkov SV et al. 2010 Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat. Med. 16, 598-602. (doi:10.1038/nm.2125)
172. Chen SK, Tvrdik P, Peden E, Cho S, Wu S, Spangrude G, Capecchi MR. 2010 Hematopoietic origin of pathological grooming in Hoxb8 mutant mice. Cell 141, 775-785. (doi:10.1016/j.cell.2010.03.055)
173. Shanahan NA, Holick Pierz KA, Masten VL, Waeber C, Ansorge M, Gingrich JA, Geyer MA, Hen R, Dulawa SC. 2009 Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice. Biol. Psychiat. 65, 401-408. (doi:10.1016/j.biopsych.2008.09.026)
174. Shanahan NA, Velez LP, Masten VL, Dulawa SC. 2011 Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice. Biol. Psychiat. 70, 1039-1048. (doi:10.1016/j.biopsych.2011.07.032)
175. Mundo E, Richter MA, Zai G, Sam F, McBride J, Macciardi F, Kennedy JL. 2002 5HT1Dbeta receptor gene implicated in the pathogenesis of obsessive-compulsive disorder: further evidence from a family-based association study. Mol. Psychiat. 7, 805-809. (doi:10.1038/sj.mp.4001059)
176. Mundo E, Richter MA, Sam F, Macciardi F, Kennedy JL. 2000 Is the 5-HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? Am. J. Psychiat. 157, 1160-1161. (doi:10.1176/appi.ajp.157.7.1160)
177. Zuchner S et al. 2009 Multiple rare SAPAP3 missense variants in trichotillomania and OCD. Mol. Psychiat. 14, 6-9. (doi:10.1038/mp.2008.83)
178. O'Sullivan RL, Keuthen NJ, Christenson GA, Mansueto CS, Stein DJ, Swedo SE. 1997 Trichotillomania: behavioral symptom or clinical syndrome? Am. J. Psychiat. 154, 1442-1449.
179. Stein MB, Schork NJ, Gelernter J. 2008 Gene-byenvironment (serotonin transporter and childhood maltreatment) interaction for anxiety sensitivity, an intermediate phenotype for anxiety disorders. Neuropsychopharmacology 33, 312-319. (doi:10.1038/sj.npp.1301422)
180. Rauch SL, Wright CI, Savage CR, Martis B, McMullin KG, Wedig MM, Gold AL, Keuthen NJ. 2007 Brain activation during implicit sequence learning in individuals with trichotillomania. Psychiat. Res. 154, 233-240. (doi:10.1016/j.pscychresns.2006.09.002)
181. Swedo SE, Rapoport JL, Leonard HL, Schapiro MB, Rapoport SI, Grady CL. 1991 Regional cerebral glucose metabolism of women with trichotillomania. Arch. Gen. Psychiat. 48, 828-833. (doi:10.1001/archpsyc.1991.01810330052008)
182. Chou-Green JM, Holscher TD, Dallman MF, Akana SF. 2003 Compulsive behavior in the 5-HT2C receptor knockout mouse. Physiol. Behav. 78, 641-649. (doi:10.1016/S0031-9384(03)00047-7)
183. Palvimaki EP, Majasuo H, Syvalahti E, Hietala J. 2005 Serotonin 5-HT2C receptor-mediated phosphoinositide hydrolysis in rat choroid plexus after fluoxetine and citalopram treatments. Pharmacol. Res. 51, 419-425. (doi:10.1016/j.phrs.2004.11.005)
184. Tecott LH, Abdallah L. 2003 Mouse genetic approaches to feeding regulation: serotonin 5-HT2C receptor mutant mice. CNS Spectrums 8, 584-588.
185. Campbell KM et al. 1999 OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1{thorn} neurons. J. Neurosci. 19, 5044-5053.
186. Nordstrom EJ, Burton FH. 2002 A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Mol. Psychiat. 7, 617-625+524. (doi:10.1038/sj.mp.4001144)
187. Cryan JF, Kelliher P, Kelly JP, Leonard BE. 1999 Comparative effects of serotonergic agonists with varying efficacy at the 5-HT(1A) receptor on core body temperature: modification by the selective 5-HT(1A) receptor antagonist WAY 100635. J. Psychopharmacol. 13, 278-283. (doi:10.1177/026988119901300310)
188. Berridge KC, Aldridge JW, Houchard KR, Zhuang X. 2005 Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's. BMC Biol. 3, 4. (doi:10.1186/1741-7007-3-4)
189. McGrath MJ, Campbell KM, Parks CR, Burton FH. 2000 Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res. 877, 23-30. (doi:10.1016/S0006-8993(00)02646-9)
190. Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, Hen R. 2001 Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl Acad. Sci. USA 98, 1982-1987. (doi:10.1073/pnas.98.4.1982)
191. Fox MA, Panessiti MG, Hall FS, Uhl GR, Murphy DL. In press. An evaluation of the serotonin system and perseverative, compulsive, stereotypical, and hyperactive behaviors in dopamine transporter (DAT) knockout mice. Psychopharmacology.
192. Fullana MA, Mataix-Cols D, Caspi A, Harrington H, Grisham JR, Moffitt TE, Poulton R. 2009 Obsessions and compulsions in the community: prevalence, interference, help-seeking, developmental stability, and co-occurring psychiatric conditions. Am. J. Psychiat. 166, 329-336. (doi:10.1176/appi.ajp.2008.08071006)
193. Hanna GL, Fingerlin TE, Himle JA, Boehnke M. 2005 Complex segregation analysis of obsessive-compulsive disorder in families with pediatric probands. Hum. Hered. 60, 1-9. (doi:10.1159/000087135)
194. Hanna GL, Fischer DJ, Chadha KR, Himle JA, Van Etten M. 2005 Familial and sporadic subtypes of early-onset obsessive-compulsive disorder. Biol. Psychiat. 57, 895-900. (doi:10.1016/j.biopsych.2004.12.022)
195. Hemmings SM, Kinnear CJ, Lochner C, Niehaus DJ, Knowles JA, Moolman-Smook JC, Corfield VA, Stein DJ. 2004 Early- versus late-onset obsessive-compulsive disorder: investigating genetic and clinical correlates. Psychiat. Res. 128, 175-182. (doi:10.1016/j.psychres.2004.05.007)
196. Ackerman DL, Greenland S, Bystritsky A. 1996 Use of receiver-operator characteristic (ROC) curve analysis to evaluate predictors of response to clomipramine therapy. Psychopharmacol. Bull. 32, 157-165.
197. Ackerman DL, Greenland S, Bystritsky A, Morgenstern H, Katz RJ. 1994 Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J. Clin. Psychopharmacol. 14, 247-254.
198. Fontenelle LF, Marques C, Versiani M. 2002 The effect of gender on the clinical features and therapeutic response in obsessive-compulsive disorder. Rev. Bras. Psiquiatr. 24, 7-11. (doi:10.1590/S1516-44462002000100005)
199. Geller DA, Biederman J, Griffin S, Jones J, Lefkowitz TR. 1996 Comorbidity of juvenile obsessive-compulsive disorder with disruptive behavior disorders. J. Am. Acad. Child Adolesc. Psychiat. 35, 1637-1646. (doi:10.1097/00004583-199612000-00016)
200. Geller DA, Biederman J, Jones J, Shapiro S, Schwartz S, Park KS. 1998 Obsessive-compulsive disorder in children and adolescents: a review. Harv. Rev. Psychiat. 5, 260-273. (doi:10.3109/10673229809000309)
201. Rosario-Campos MC et al. 2001 Adults with earlyonset obsessive-compulsive disorder. Am. J. Psychiat. 158, 1899-1903. (doi:10.1176/appi.ajp.158.11.1899)
202. Zohar AH, Ratzoni G, Pauls DL, Apter A, Bleich A, Kron S, Rappaport M, Weizman A, Cohen DJ. 1992 An epidemiological study of obsessive-compulsive disorder and related disorders in Israeli adolescents. J. Am. Acad. Child Adolesc. Psychiat. 31, 1057-1061. (doi:10.1097/00004583-199211000-00010)
203. Schooler C, Revell AJ, Timpano KR, Wheaton M, Murphy DL. 2008 Predicting genetic loading from symptom patterns in obsessive-compulsive disorder: a latent variable analysis. Depress. Anxiety 25, 680-688. (doi:10.1002/da.20444)
204. Mataix-Cols D, Rosario-Campos MC, Leckman JF. 2005 A multidimensional model of obsessive-compulsive disorder. Am. J. Psychiat. 162, 228-238. (doi:10.1176/appi.ajp.162.2.228)
205. Abramowitz JS, Franklin ME, Schwartz SA, Furr JM. 2003 Symptom presentation and outcome of cognitive-behavioral therapy for obsessive-compulsive disorder. J. Consult. Clin. Psychol. 71, 1049-1057. (doi:10.1037/0022-006X.71.6.1049)
206. Black DW, Monahan P, Gable J, Blum N, Clancy G, Baker P. 1998 Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J. Clin. Psychiat. 59, 420-425. (doi:10.4088/JCP.v59n0804)
207. Winsberg ME, Cassic KS, Koran LM. 1999 Hoarding in obsessive-compulsive disorder: a report of 20 cases. J. Clin. Psychiat. 60, 591-597. (doi:10.4088/JCP.v60n0905)
208. Samuels JF, Bienvenu OJ, Grados MA, Cullen B, Riddle MA, Liang KY, Eaton WW, Nestadt G. 2008 Prevalence and correlates of hoarding behavior in a community-based sample. Behav. Res. Ther. 46, 836-844. (doi:10.1016/j.brat.2008.04.004)
209. Samuels JF et al. 2008 Sex-specific clinical correlates of hoarding in obsessive-compulsive disorder. Behav. Res. Ther. 46, 1040-1046. (doi:10.1016/j.brat.2008.06.005)
210. Wheaton M, Timpano KR, Lasalle-Ricci VH, Murphy D. 2008 Characterizing the hoarding phenotype in individuals with OCD: associations with comorbidity, severity and gender. J. Anxiety Disord. 22, 243-252. (doi:10.1016/j.janxdis.2007.01.015)
211. Grisham JR, Brown TA, Liverant GI, Campbell-Sills L. 2005 The distinctiveness of compulsive hoarding from obsessive-compulsive disorder. J. Anxiety Disord. 19, 767-779. (doi:10.1016/j.janxdis.2004.09.003)
212. Wu KD, Watson D. 2005 Hoarding and its relation to obsessive-compulsive disorder. Behav. Res. Ther. 43, 897-921. (doi:10.1016/j.brat.2004.06.013)
213. Frost RO, Steketee G, Williams LF, Warren R. 2000 Mood, personality disorder symptoms and disability in obsessive compulsive hoarders: a comparison with clinical and nonclinical controls. Behav. Res. Ther. 38, 1071-1081. (doi:10.1016/S0005-7967(99)00137-0)
214. Samuels J, Bienvenu III OJ, Riddle MA, Cullen BA, Grados MA, Liang KY, Hoehn-Saric R, Nestadt G. 2002 Hoarding in obsessive compulsive disorder: results from a case-control study. Behav. Res. Ther. 40, 517-528. (doi:10.1016/S0005-7967(01)00026-2)
215. Samuels JF et al. 2007 Hoarding in obsessive-compulsive disorder: results from the OCD collaborative genetics study. Behav. Res. Ther. 45, 673-686. (doi:10.1016/j.brat.2006.05.008)
216. Abramowitz JS, Wheaton MG, Storch EA. 2008 The status of hoarding as a symptom of obsessive-compulsive disorder. Behav. Res. Ther. 46, 1026-1033. (doi:10.1016/j.brat.2008.05.006)
217. Pertusa A, Fullana MA, Singh S, Alonso P, Menchon JM, Mataix-Cols D. 2008 Compulsive hoarding: OCD symptom, distinct clinical syndrome, or both? Am. J. Psychiat. 165, 1289-1298. (doi:10.1176/appi.ajp.2008.07111730)
218. Zhang H, Leckman JF, Pauls DL, Tsai CP, Kidd KK, Campos MR. 2002 Genomewide scan of hoarding in sib pairs in which both sibs have Gilles de la Tourette syndrome. Am. J. Hum. Genet. 70, 896-904. (doi:10.1086/339520)
219. Leckman JF, Bloch MH. 2008 A developmental and evolutionary perspective on obsessive-compulsive disorder: whence and whither compulsive hoarding? Am. J. Psychiat. 165, 1229-1233. (doi:10.1176/appi.ajp.2008.08060891)
220. Mataix-Cols D, Frost RO, Pertusa A, Clark LA, Saxena S, Leckman JF, Stein DJ, Matsunaga H, Wilhelm S. 2010 Hoarding disorder: a new diagnosis for DSM-V. Depress. Anxiety 27, 556-572. (doi:10.1002/da.20693)
221. Graybiel AM. 2008 Habits, rituals, and the evaluative brain. Annu. Rev. Neurosci. 31, 359-387. (doi:10.1146/annurev.neuro.29. 051605.112851)
222. Cavallini MC, Di Bella D, Siliprandi F, Malchiodi F, Bellodi L. 2002 Exploratory factor analysis of obsessive-compulsive patients and association with 5-HTTLPR polymorphism. Am. J. Med. Genet. 114, 347-353. (doi:10.1002/ajmg.1700)
223. Miguel EC, Leckman JF, Rauch S, do Rosario-Campos MC, Hounie AG, Mercadante MT, Chacon P, Pauls DL. 2005 Obsessive-compulsive disorder phenotypes: implications for genetic studies. Mol. Psychiat. 10, 258-275. (doi:10.1038/sj.mp.4001617)
224. Atmaca M, Yildirim BH, Ozdemir BH, Aydin BA, Tezcan AE, Ozler AS. 2006 Volumetric MRI assessment of brain regions in patients with refractory obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiat. 30, 1051-1057. (doi:10.1016/j.pnpbp.2006.03.033)
225. Soriano-Mas C, Pujol J, Alonso P, Cardoner N, Menchon JM, Harrison BJ, Deus J, Vallejo J, Gaser C. 2007 Identifying patients with obsessive- compulsive disorder using whole-brain anatomy. NeuroImage 35, 1028-1037. (doi:10.1016/j.neuroimage.2007.01.011)
226. Menzies L, Achard S, Chamberlain SR, Fineberg N, Chen CH, del Campo N, Sahakian BJ, Robbins TW, Bullmore E. 2007 Neurocognitive endophenotypes of obsessive-compulsive disorder. Brain 130, 3223-3236. (doi:10.1093/brain/awm205)
227. Chamberlain SR et al. 2008 Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science 321, 421-422. (doi:10.1126/science.1154433)
228. Greenberg BD, Rauch SL, Haber SN. 2010 Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD. Neuropsychopharmacology 35, 317-336. (doi:10.1038/npp.2009.128)
229. Murphy DL, Pigott TA. 1990 A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. J. Clin. Psychiat. 51(Suppl. 53-58); discussion 9-60.
230. Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, Phelps ME, Baxter LR. 1999 Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 21, 683-693. (doi:10.1016/S0893-133X(99)00082-2)
231. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter Jr LR. 2003 Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am. J. Psychiat. 160, 522-532. (doi:10.1176/appi.ajp.160.3.522)
232. Sattler R, Rothstein JD. 2007 Targeting an old mechanism in a new disease-protection of glutamatergic dysfunction in depression. Biol. Psychiat. 61, 137-138. (doi:10.1016/j.biopsych.2006.11.011)
233. Delgado PL, Goodman WK, Price LH, Heninger GR, Charney DS. 1990 Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br. J. Psychiat. 157, 762-765. (doi:10.1192/bjp.157.5.762)
234. Maina G, Pessina E, Albert U, Bogetto F. 2008 8-Week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 18, 364-372. (doi:10.1016/j.euroneuro.2008.01.001)
235. Grisham JR, Anderson TM, Sachdev PS. 2008 Genetic and environmental influences on obsessive-compulsive disorder. Eur. Arch. Psychiat. Clin. Neurosci. 258, 107-116. (doi:10.1007/s00406-007-0789-0)
236. Cromer KR, Schmidt NB, Murphy DL. 2007 Do traumatic events influence the clinical expression of compulsive hoarding? Behav. Res. Ther. 45, 2581-2592. (doi:10.1016/j.brat.2007.06.005)
237. Cromer KR, Schmidt NB, Murphy DL. 2007 An investigation of traumatic life events and obsessive-compulsive disorder. Behav. Res. Ther. 45, 1683-1691. (doi:10.1016/j.brat.2006.08.018)
238. Binder EB et al. 2008 Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. J. Am. Med. Assoc. 299, 1291-1305. (doi:10.1001/jama.299.11.1291)
239. Grabe HJ, Lange M, Wolff B, Volzke H, Lucht M, Freyberger HJ, John U, Cascorbi I. 2005 Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden. Mol. Psychiat. 10, 220-224. (doi:10.1038/sj.mp.4001555)
240. Koenen KC. 2007 Genetics of posttraumatic stress disorder: review and recommendations for future studies. J. Trauma Stress 20, 737-750. (doi:10.1002/jts.20205)
241. Sasson Y, Dekel S, Nacasch N, Chopra M, Zinger Y, Amital D, Zohar J. 2005 Posttraumatic obsessive-compulsive disorder: a case series. Psychiat. Res. 135, 145-152. (doi:10.1016/j.psychres. 2004.05.026)
242. Lipinski JJ. 1994 Do 'flashbacks' represent obsessional imagery? Compr. Psychiat. 35, 245-247. (doi:10.1016/0010-440X(94)90014-0)
243. Gershuny BS, Baer L, Radomsky AS, Wilson KA, Jenike MA. 2003 Connections among symptoms of obsessive-compulsive disorder and posttraumatic stress disorder: a case series. Behav. Res. Ther. 41, 1029-1041. (doi:10.1016/S0005-7967(02) 00178-X)
244. Gershuny BS, Baer L, Parker H, Gentes EL, Infield AL, Jenike MA. 2008 Trauma and posttraumatic stress disorder in treatment-resistant obsessive-compulsive disorder. Depress. Anxiety 25, 69-71. (doi:10.1002/da.20284)
245. Grabe HJ et al. 2008 Obsessive-compulsive disorder and posttraumatic stress disorder. Psychopathology 41, 129-134. (doi:10.1159/000112029)
246. Berthier ML, Kulisevsky J, Gironell A, Lopez OL. 2001 Obsessive-compulsive disorder and traumatic brain injury: behavioral, cognitive, and neuroimaging findings. Neuropsychiat. Neuropsychol. Behav. Neurol. 14, 23-31.
247. Coetzer R, Stein DJ, Du Toit PL. 2001 Executive function in traumatic brain injury and obsessive- compulsive disorder: an overlap? Psychiat. Clin. Neurosci. 55, 83-87. (doi:10.1046/j.1440-1819.2001.00792.x)
248. Grados MA. 2003 Obsessive-compulsive disorder after traumatic brain injury. Int. Rev. Psychiat. 15, 350-358. (doi:10.1080/09540260310001606737)
249. Silver JM, Kramer R, Greenwald S, Weissman M. 2001 The association between head injuries and psychiatric disorders: findings from the New Haven NIMH epidemiologic catchment area study. Brain Inj. 15, 935-945. (doi:10.1080/02699050110065295)
250. McKeon J, Roa B, Mann A. 1984 Life events and personality traits in obsessive-compulsive neurosis. Br. J. Psychiat. 144, 185-189. (doi:10.1192/bjp.144.2.185)
251. Kant R, Smith-Seemiller L, Duffy JD. 1996 Obsessive-compulsive disorder after closed head injury: review of literature and report of four cases. Brain Inj. 10, 55-63. (doi:10.1080/026990596124728)